App Orchid, a Google Cloud Cortex Framework partner, will enable customers to ask natural language questions and get ...

Google has released a whole new range of AI-powered research and interactions that simply can't be matched by DeepSeek or OpenAI.

The US Food and Drug Administration has approved suzetrigine (Journavx) 50 mg oral tablets, a first-in-class non-opioid ...

App Orchid acts as an insights layer for Cortex Framework-grounded data, powered by Google's Gemini Models and Vertex AI. Users can ask natural language questions and get answers in the form of ...

Vertex Pharmaceuticals Incorporated VRTX announced that the FDA has approved its oral, non-opioid, highly selective NaV1.8 pain signal inhibitor, suzetrigine, for the treatment of adults with moderate ...

The stock of Vertex Pharmaceuticals Incorporated VRTX has declined almost 13% in the past six months. A key reason for the stock price decline was unimpressive data from a phase II study on its key ...

Plus: A new non-opioid painkiller, the wave of lawsuits against Trump EOs, a key vote for RFK Jr., a big radiopharma deal and more.

First Drug Approved in New Class of Non-Opioid Pain Medicines; Agency Continues to Take Steps to Support New Approaches for Pain Management Journavx is the first drug to be approved in this new class ...

The U.S. Food and Drug Administration (FDA) on Thursday approved Journavx, the first new class of pain medication in more ...

New Alzheimer's drugs are beginning to be used in Sweden, more deals in the neuro sector are expected, and tools for deliver ...